{"disease":{"id":"castration-resistant-prostatic-neoplasms","name":"castration resistant prostatic neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06136650","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06785636","title":"Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Pathos AI, Inc.","has_results":false},{"nct_id":"NCT04381832","title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT05413850","title":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":82,"lead_sponsor_name":"Blue Earth Therapeutics Ltd","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT04249947","title":"P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Poseida Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03551782","title":"A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06706921","title":"18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"VA Greater Los Angeles Healthcare System","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}